DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1003070
Title:
Assessing EphA2 and Ephrin-A as Novel Diagnostic and Prognostic Biomarkers of Prostate Cancer
Descriptive Note:
Technical Report,29 Sep 2014,28 Sep 2015
Corporate Author:
Case Western Reserve University Cleveland United States
Report Date:
2015-10-01
Pagination or Media Count:
10.0
Abstract:
This study seeks to evaluate EphA2 and ephrin-A1 as novel biomarkers of prostate cancer PCa diagnosis andorprognosis. We are recruiting men at high risk for PCa who are undergoing prostate biopsy and prostatectomy at our institution. We will correlate their levels of EphA2 and ephrin-A1 mRNA as well as staining of phosphorylated pS897-EphA2 to the presence of PCa, the aggressiveness of PCa as determined by traditional clinical predictors, and race. Completion of the studies will achieve the following 1 Novel biomarkers to improve the ability to distinguish between indolent and aggressive PCa 2 More accurate prediction of disease outcomes to facilitate optimal treatment selection for each patient 3 Elucidation of the biological mechanisms behind the PCa health disparities that affect minority men. During this last study period, we have enrolled 60 male patients into our study 60 African American, 35 Caucasian, 5 Asian. After receiving approval from the USAMRMC ORP HRPO, we have collected prostate tissue cores from each patient and are in the process of optimizing our protocol for RNA extraction and quantitative RT-PCR analysis Specific Aims 1,2. Of these 60 patients, 14 70 African American, 30 Caucasian have undergone radical prostatectomy within the last study period, and we have obtained histologically confirmed benign and malignant prostate specimens from each. These specimens will be analyzed as previously described for Specific Aim 3.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
